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Abstract
Background: In this paper, we describe the clinical and neuropathological findings of nine members of the Belgian
progranulin gene (GRN) founder family. In this family, the loss-of-function mutation IVS1 + 5G > C was identified in
2006. In 2007, a clinical description of the mutation carriers was published that revealed the clinical heterogeneity
among IVS1 + 5G > C carriers. We report our comparison of our data with the published clinical and
neuropathological characteristics of other GRN mutations as well as other frontotemporal lobar degeneration (FTLD)
syndromes, and we present a review of the literature.
Methods: For each case, standardized sampling and staining were performed to identify proteinopathies,
cerebrovascular disease, and hippocampal sclerosis.
Results: The neuropathological substrate in the studied family was compatible in all cases with transactive
response DNA-binding protein (TDP) proteinopathy type A, as expected. Additionally, most of the cases presented
also with primary age-related tauopathy (PART) or mild Alzheimer’s disease (AD) neuropathological changes, and
one case had extensive Lewy body pathology. An additional finding was the presence of cerebral small vessel
changes in every patient in this family.
Conclusions: Our data show not only that the IVS1 + 5G > C mutation has an exclusive association with FTLD-TDP
type A proteinopathy but also that other proteinopathies can occur and should be looked for. Because the
penetrance rate of the clinical phenotype of carriers of GRN mutations is age-dependent, further research is
required to investigate the role of co-occurring age-related pathologies such as AD, PART, and cerebral small vessel
disease.
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Background
Frontotemporal lobar degeneration (FTLD) accounts
for 10–15% of all dementias and represents the sec-
ond most common cause of young-onset dementia.
FTLD is always associated with atrophy of the frontal
and/or temporal lobes and is sometimes markedly
asymmetrical. The clinical phenotype of FTLD
includes two major cognitive syndromes: behavioral
variant frontotemporal dementia (bvFTD) and primary
progressive aphasia (PPA) [1–3]. FTLD is often asso-
ciated with extrapyramidal symptomatology, being
referred to as frontotemporal lobar degeneration with
parkinsonism (FTDP), or with motor neuron disorders
(FTLD-MNDs), of which amyotrophic lateral sclerosis
(ALS) is the most common.
A familial history is present in up to 40% of patients
with FTLD, with a pattern suggestive of autosomal dom-
inant inheritance in 10–20% of FTLD families. In 1998,
frontotemporal dementia associated with parkinsonism
was linked to chromosome 17 (FTDP-17), leading to the
discovery of the microtubule-associated protein tau gene
(MAPT) [4–6] in 1998 and of the progranulin gene
(GRN) in 2006 [7, 8].
Mutations in MAPT are often associated with tau ag-
gregates (FTLD-tau), whereas transactive response
DNA-binding protein 43 (TDP-43) inclusions (FTLD-
TDP) are found in patients with mutations in the
C9orf72 [9–11], GRN [7, 12], valosin-containing protein
gene (VCP) [13], TARDBP [14], or TBK1 genes [15].
Rare proteinopathies include FTLD-UPS (ubiquitin
proteasome system), caused by mutations in chromatin-
modifying protein 2B (CHMP2B) [16, 17] and FTLD-
FUS (fused in sarcoma) [18], or FTLD with inclusions
belonging to other proteins of the FET family (FUS,
EWSR1, and TAF15 family of proteins) [19], for which
the underlying genetic causes are still unknown.
TDP proteinopathies are classified into four sub-
types, A through D [20]. TDP type A is characterized
by many neuronal intracytoplasmic inclusions (NCIs)
and short dystrophic neurites (DNs) predominantly in
the second cortical layer, whereas TDP type B is rep-
resented by a moderate amount of NCIs and few
DNs, present in all cortical layers. Type C inclusions
are typically long DNs, mainly in the second cortical
layer. TDP type D inclusions are characterized by
many neuronal intranuclear inclusions (NIIs). Because
the neuropathological diagnosis has a variable link
with the clinical picture, the connection with the
causative gene mutations is much stronger. GRN muta-
tions are associated with FTLD-TDP type A. Mutations in
GRN cause 15–40% of FTLD-TDP cases [21–24]. In
Belgium, GRN mutations are the second most prevalent
mutations causing FTLD, with C9orf72 G4C2 repeat
expansions being the most prevalent [25].
The penetrance rate seems to be age-dependent, just
as it is in C9orf72 mutations [25]. Gass et al. found that
by the age of 60, nearly 50% of the carriers were affected,
whereas 90% of patients showed symptomatology by the
age of 90 [22]. The heterogeneity of the clinical pheno-
types in GRN mutations and the incomplete penetrance
of a mutation [26] can make it difficult to recognize an
autosomal dominant pattern of inheritance.
GRN is located on chromosome 17q21, and the first
loss-of-function mutations in GRN were identified in
2006 [7, 8]. Cruts et al. described a point mutation in
the splice donor site of intron 1 (IVS1 + 5G > C) in the
Belgian DR8 family [8, 12]. Consequently, intron 1 spli-
cing is prohibited, and the mutant transcript is retained
in the nucleus, where it is degraded, leading to a null al-
lele and 50% of GRN production. This mutation was
shown to be a founder mutation and is the most fre-
quent GRN mutation in patients with frontotemporal
dementia (FTD) in the Belgian Flanders population [8]
(Wauters E, Van Mossevelde S, Sleegers K: Phenotypic
characteristics and genetic onset age modifiers in an ex-
tended Belgian GRN founder family. Submitted). Since
the identification of GRN, 172 different mutations have
been described (http://www.molgen.ua.ac.be) [27]. Next
to null mutations [28], partial deletions of the GRN gene
have also been described in FTLD [29, 30]. GRN mis-
sense mutations have also been observed in Alzheimer’s
disease (AD) and ALS [31–33].
Progranulin is a growth factor expressed by many
cells, including neurons. Progranulin can be cleaved to
form smaller peptides, called granulins, which have an
additional role in inflammation, wound repair, and cell
cycling [24]. As a result of the haploinsufficiency, low
progranulin levels are found in the plasma, serum, and
cerebrospinal fluid of symptomatic and asymptomatic
GRN mutation carriers and were also present in the fam-
ily we are presently reporting [34, 35].
Cerebral small vessel disease (SVD) is a common find-
ing in the elderly brain, and its pathology appears in the
presence of risk factors such as smoking habit, hyperten-
sion, hypercholesterolemia, and diabetes mellitus. There
is a known link with AD and Lewy body disease [36],
but to date there are no data regarding SVD in patients
carrying a GRN mutation. De Reuck et al. found no cere-
brovascular changes in 22 patients with FTLD, 2 of
whom carried a GRN mutation [37]. Because Thal et al.
recently found an association between cerebral SVD and
Pick’s disease [38], it is of interest whether cerebral SVD
could play a role in this disease.
We characterized the neuropathological data of nine
members of the Belgian GRN founder family in an
extensive sampling of brain regions, and we compared
our data with the published clinical and neuropatho-
logical characteristics of other GRN mutations and other
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FTLD syndromes. Furthermore, because white matter
pathology is a common finding on cerebral structural
imaging of GRN mutation carriers, and because this
finding was also observed in our GRN founder family,
we examined the white matter and cerebral small vessels
in different brain regions in this family.
Methods
Neuropathological evaluation was carried out in nine
members of an extended family of patients with FTLD
carrying the GRN IVS1 + 5G > C mutation, which was
previously reported in 2006 [8]. Neuropathological
findings of one patient in this family (DR205.1) were
previously described with the techniques available at that
time. The nine patients were members of six different
branches of the GRN founder family (for pedigree, see
(Wauters E, Van Mossevelde S, Sleegers K: Phenotypic
characteristics and genetic onset age modifiers in an ex-
tended Belgian GRN founder family. Submitted)). All
available clinical and iconographical data of these pa-
tients were reviewed. Because the subjects originated
from different regions in Flanders (Belgium), they were
followed by different neurologists in different centers.
Consequently, the diagnostic approaches and performed
investigations or neuropsychological tests done during
the patients’ lifetimes varied between patients and in the
clinical data. For most of the patients, we had access to
clinical data concerning medical history, clinical neuro-
logical evaluations, neuropsychological evaluations, and
brain imaging (structural and functional). The right
hemisphere was neuropathologically examined, as was
the circle of Willis when present.
We used standardized sampling and staining tech-
niques (see Additional file 1) to identify histological
changes, proteinopathies, and cerebral small vessel path-
ology. For AD neuropathological diagnosis and for its
clinicopathological correlation, the criteria of Montine et
al. were used [39]; for Lewy body pathology, the classifi-
cation of McKeith et al. was used [40]; and for TDP pro-
teinopathies, we used the Mackenzie et al. criteria [20].
For staging of cerebrovascular pathology, we refer to the
work of Deramecourt et al. [36], and for the
clinicopathological correlations of the cerebrovascular
pathology, we refer to the work by Skrobot et al. [41].
The methodological data concerning DNA extraction,
clinical findings, neuropsychological assessments, and




Macroscopic findings in eight of nine patients (no data
available for patient DR205.1) were compatible with
moderate to severe frontal atrophy, with a relative
sparing of the precentral gyrus (Fig. 1a, b; Table 1). To a
lesser extent, temporal and/or parietal cortices (Fig. 1d)
were also atrophied, in addition to the head of the caud-
ate nucleus (Fig. 1c). For the full macroscopic data, see
Additional file 2. Because our research protocol included
the preservation of the left hemisphere at −80 °C, state-
ments about asymmetry were not possible.
In three of six patients, we saw mild atherosclerotic
plaques or minimal fibrotic changes in the arteries of the
circle of Willis.
Histological findings
In all patients, a moderate to severe cortical neuronal loss
with astrocytosis was seen in Brodmann area 24, more
than in areas 6–8 and 11 and more than in precentral area
4. The temporal neocortex was atrophic in three cases,
whereas every case presented with mild to moderate neur-
onal loss in CA1, the subiculum, and the pro- and parasu-
biculum (Table 2). There was severe atrophy in the
neostriatum; the substantia nigra had substantial neuronal
loss in all cases, whereas the locus coeruleus was affected
in four of nine patients. There were no abnormalities in
the cerebellum or thalamus. Figure 2 summarizes the
major histological abnormalities.
Small vessel disease
In every patient, small vessel changes were present.
Trichrome staining showed a preferential thickening of
the arteriolar wall in cortex and white matter. (Small ar-
teries were defined as arterioles when the diameter was
between 40 and 150 μm [36].) Arteriolosclerosis was
characterized by thickening of the vessel wall and re-
duplication of the internal elastic layer. Other features of
SVD included a dilation of the perivascular space, peri-
vascular demyelination, and perivascular hemosiderin
leakage (Fig. 3). The staging system of Deramecourt et
al. [36] was used to semiquantify SVD. In the frontal
lobes, SVD was more severe than in the temporal lobes,
basal ganglia, and hippocampus (Table 3). Using the vas-
cular cognitive impairment neuropathological guidelines,
on the basis of the presence of leptomeningeal cerebral
amyloid angiopathy, subcortical macroinfarcts, and
arteriolosclerosis in the occipital lobe, we could estimate
that there was a low likelihood that the cerebrovascular
pathology contributed to the cognitive decline in our
cases (Table 3).
Immunohistology
In all patients, TDP proteinopathy type A could be diag-
nosed (Fig. 4). Lesions were, as expected, more severe in
the frontal and temporal neocortices. In the frontal cor-
tex, most lesions were found in areas 6 and 8, area 24,
and area 11, compared with prefrontal area 4. The tem-
poral superior gyrus demonstrated a moderate to high
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Fig. 1 Macroscopic images. a Lateral view of the right hemisphere in DR2.3. Note the frontal and temporal, and to a lesser extent parietal, atrophy.
Area 4 (arrow) is relatively preserved. b Medial view of right hemisphere in DR2.3. The superior frontal gyrus is atrophied, whereas the straight gyrus is
relatively spared. c Coronal section of the right hemisphere trough the head of the caudate nucleus in DR2.3. There is a flattened, nearly concave
aspect of the caudate nucleus. d Coronal sections trough the parietotemporal lobes in DR8.1. The lateral ventricle is dilated, especially the temporal
horn. Temporal atrophy is more pronounced than parietal atrophy
Table 1 Macroscopic findings
Atrophy location DR2.3 DR8.1 DR25.1 DR25.5 DR28.1 DR205.1 DR31.1 DR1207.1 DR1213.1
Frontal lobe +++ +++ +++ +++ +++ NA + +++ +++
Temporal lobe +++ + + +++ + NA + ++ +
Parietal lobe + − ++ − +++ NA − − −
Caudate nucleus + + NA + + NA + +++ +++
Whole cortical atrophy + − − − − NA − − −
Weight of right hemisphere 414 g 519 g 449 g 472 g 583 g NA NA 522 g 577 g
NA Not available, + Mild atrophy, ++ Moderate atrophy, +++ Severe atrophy
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lesion load, whereas only a mild to moderate amount of
TDP pathology was present in the hippocampal and
parahippocampal structures.
In eight patients (no data available for DR205.1), there
was mild to moderate TDP-43 proteinopathy in the par-
ietal cortex (area 7), whereas in four of eight patients,
the occipital lobe was affected. In the neostriatum, le-
sions were moderate to numerous and were evenly
spread throughout the caudate nucleus and putamen.
Sparse lesions were found in the dorsomedial formation
of the thalamus in seven of nine patients.
Glial cytoplasmic inclusions (GCIs) were found in
the subcortical and deeper white matter of the frontal
and parietal lobes and rarely in the mesotemporal
white matter. Except for rare DNs and occasional
GCIs, no inclusions were found in the substantia
nigra, pons, or medulla oblongata. No NCIs were
present in the neurons of the hypoglossal nucleus.
The cerebellum was normal.
The degree of TDP-43 inclusions was moderate, varying
from sparse (0–1/mm2) (±), to mild (<5/mm2) (+), to mod-
erate (5–20/mm2) (++), to extensive (> 20/mm2) (+++).
The most common lesions were skein-like NCIs and short
DNs. Sporadically, cat’s-eye NIIs were found, mainly in the
frontotemporal neocortex. The lesion load was most pro-
found in the second cortical layer. A summary of the TDP
pathology is presented in Fig. 5.
In all patients, FUS and prion staining was negative.
P62 stain could not elicit any additional pathology. In all
patients, AD-related pathology was found; however, the
lesion load remained mild. Two patients had A1B1C1
(DR2.3, DR31.1), one patient presented with A2B1C1
(DR205.1), and one patient presented with A3B1C1
(DR28.1). The five remaining patients presented with
neurofibrillary tangles in the hippocampus and parahip-
pocampal gyrus without β-amyloid pathology, diagnosed
as AD neuropathological changes A0B1C0 [39], also re-
ferred to as primary age-related tauopathy (PART) [42].
Table 2 Co-occurring Alzheimer’s disease pathology and clinicopathological correlation, hippocampal neuronal loss, and
apolipoprotein E genotype




DR2.3 A1B1C1 2 2 1 Low 2 Ɛ2/Ɛ3
DR8.1 A0B1C0 0 1 0 Not 2 Ɛ3/Ɛ3
DR25.1 A0B1C0 0 1 0 Not 1 Ɛ3/Ɛ3
DR25.5 A0B1C0 0 1 0 Not 2 Ɛ3/Ɛ3
DR28.1 A3B1C1 5 1 1 Low 0 Ɛ3/Ɛ4
DR205.1 A2B1C1 3 2 1 Low 1 Ɛ2/Ɛ4
DR31.1 A1B1C1 2 1 1 Low 1 Ɛ2/Ɛ3
DR1207.1 A0B1C0 0 1 0 Not 1 Ɛ3/Ɛ3
DR1213.1 A0B1C0 0 1 0 Not 2 Ɛ3/Ɛ3
ApoE Apolipoprotein E, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
Column 2: Montine classification [39, 83]; column 3: Thal stages for β-amyloid plaques [84]; column 4: Braak stages for neurofibrillary changes [85]; column 5:
CERAD stages for senile plaques [86]: 0 = no pathology, 1 = sparse CERAD score; column 6: clinicopathological correlation of Alzheimer’s disease neuropathological
changes [39]; column 7: neuronal loss in hippocampal CA1 (scale 0–3): 0 = no pathology, 1 =mild neuronal loss, 2 = moderate neuronal loss; column 8:
ApoE genotype
Fig. 2 Grouped histopathological findings. Entorhinal cortex (ER), transentorhinal cortex (TER), gyrus occipitotemporalis lateralis (GOTL),
dorsomedial formation (DMF), and status pigmentatus (SP). Semiquantitative analysis of the average neuronal cell loss in every region of interest.
nl Normal, ↓ Slight neuronal loss, ↓↓ Moderate neuronal loss, ↓↓↓ Severe neuronal loss
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Table 2 summarizes the AD neuropathological changes
using the Montine criteria, as well as the clinicopatho-
logical correlation.
One patient (DR205.1) clinically presented with a
combination of FTLD and Parkinson’s disease (PD). This
case revealed many Lewy bodies in the substantia nigra
and the formatio reticularis, and to a lesser extent in the
frontal and temporal cortices, the hippocampus, and the
parahippocampal gyrus. A dual diagnosis of FTLD-TDP
type A and diffuse Lewy body disease, neocortical type,
was made [40].
Clinical, neuropsychological, and imaging data
We evaluated nine patients (four females, five males).
Symptomatology started between the ages of 55 and
70 years, with a mean onset age of 62. The disease
lasted, on average, 5.3 years (range 2.3–8.6). The mean
age at death was 67 years (range 60–75). Symptom-
atology was mostly frontotemporal (four of nine
bvFTD, four of nine PPA), except in one patient who
was clinically diagnosed with PD (DR205.1). This pa-
tient developed frontotemporal symptoms as well,
later in the disease. The demographic characteristics
of the evaluated patients are summarized in Table 4,
whereas the clinical and neuropsychological character-
istics, as well as imaging data, are discussed in Add-
itional files 3 and 4. Table 5 summarizes the
cerebrovascular risk factors.
Discussion
This report describes the clinical and neuropathological
findings in nine members of a Belgian GRN founder
family. This extended Belgian founder family was first
described by van der Zee et al. in 2006 after the identifi-
cation of an ancestral haplotype at 17q21 in seven (unre-
lated) familial tau-negative patients with FTLD. The
IVS1 + 5G > C GRN mutation was found as a causal gene
defect [8]. This family has been further explored, and to
date we have genealogical data of 29 branches over 5
generations.
Neuropathology
Severe frontal and temporal neocortical loss was ob-
served. Next to the neocortical atrophy, every patient
had a neuronal cell loss in CA1 and the subiculum.
There was no hippocampal sclerosis. These findings are
Fig. 3 Cerebral small vessel disease. a DR2.3. H&E stain of perivascular hemosiderin deposits in the hippocampus. Arrows show many
siderophages. b DR25.5. H&E stain of the corpus callosum. Arrows show thickening of the arteriolar wall. c DR25.5. H&E stain of the temporal
white matter. Arrows show thickening of the arteriolar walls with mild perivascular demyelination
Table 3 Cerebral small vessel disease and its clinicopathological correlation
Identifier Frontal Temporal Hippocampal Basal ganglia Total score CAA Large infarcts Arteriolosclerosis Correlation
DR2.3 1 1 1 2 5 0 0 0 Low
DR8.1 2 2 2 1 7 1 0 1 Low
DR25.1 2 1 2 1 6 0 0 0 Low
DR25.5 2 2 1 1 6 0 0 2 Low
DR28.1 1 1 1 1 4 0 0 1 Low
DR205.1 NA NA 2 1 NA NA NA NA Low
DR31.1 2 1 1 1 5 0 0 1 Low
DR1207.1 2 1 1 1 5 0 0 1 Low
DR1213.1 1 1 1 2 5 0 0 0 Low
CAA Leptomeningeal cerebral amyloid angiopathy, NA Not applicable
Deramecourt staging of cerebrovascular pathology in dementia in frontal lobe, temporal lobe, and hippocampus, with total score (total possible score = 20) [36].
For the likelihood that cerebral small vessel disease (SVD) contributed to cognitive decline, we refer to the work of Skrobot et al. [41]. Large infarcts: one or more
subcortical infarcts with diameter > 10 mm; arteriolosclerosis: arteriolosclerosis in the occipital lobe. Correlation: likelihood that SVD contributed to
cognitive decline
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comparable with the data published by Josephs et al. in
2007 [43]. In all our cases, TDP-43 type A proteinopathy
was observed, confirming previously published data [20].
We compared our neuropathological data in these pa-
tients with data of patients in our database carrying
other GRN mutations (n = 2), C9orf72 expansion repeat
mutations (n = 15), TBK1 mutations (n = 2), and VCP
mutations (n = 3) [15, 25, 44, 45]. In our study, the pres-
ence of a TDP type A proteinopathy and the absence of
dipeptide repeat pathology in the dentate gyrus and
hippocampus allowed us to differentiate between GRN
and C9orf72 mutations. We found no differences in
Fig. 4 Transactive response DNA-binding protein (TDP) pathology (paraffin-embedded sections stained with antihyperphosphorylated TDP-43
antibody). a DR25.5 area 6. There is a moderate amount of neuronal intracytoplasmic inclusions (NCIs) (arrows), mainly in the second cortical layer.
The dystrophic neurites (arrowhead) are more evenly spread throughout the entire cortex. b DR2.3 superior temporal gyrus. Mild to moderate
TDP-43 proteinopathy type A with NCIs (arrow) and dystrophic neurites (arrowheads) can be seen. c DR28.1 dentate gyrus. There are scarce NCIs
(arrow) in the granular layer. d DR31.1 area striata. A mild amount of NCIs (arrows) and dystrophic neurites (arrowheads) in the second cortical
layer can be seen
Fig. 5 Transactive response DNA-binding protein pathology in different brain areas. ± (sparse (0–1/mm2)), + (mild (< 5/mm2)), ++ (moderate (5–20/mm2)),
+++ (extensive (> 20/mm)). The average lesion load is shown for the most important regions of interest. Striped bar represents the amount of neuronal
intracytoplasmic inclusions, whereas the dark bar represents the amount of short dystrophic neurites. With the dotted bar, the neuronal intranuclear
inclusions are shown. NCI Neuronal intracytoplasmic inclusions, DN Dystrophic neurites, NII Nuclear intraneuronal inclusions, DMF Dorsomedial formation,
ER Entorhinal cortex, TER Transentorhinal cortex, GOTL Gyrus occipitotemporalis lateralis, DG Dentate gyrus
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TDP lesion load between the IVS1 + 5G > C GRN muta-
tion and other GRN mutations. We observed that, com-
pared with the C9orf72 carriers, the precentral cortex
area 4 was less affected. In both GRN and C9orf72 car-
riers, parietal involvement was present; however, it was
less explicit than frontotemporal atrophy. In four pa-
tients carrying the IVS1 + 5G > C GRN mutation, we also
found a mild TDP proteinopathy in the occipital cortex.
In the TBK1 carriers, the neuropathological diagnosis
was compatible with a TDP type B proteinopathy, with
involvement of all the frontal and temporal neocortices,
the hippocampal dentate gyrus, the parahippocampal
transentorhinal cortex, the neostriatum, and the palli-
dum. TDP pathology was also present in motor neurons,
whereas in the GRN patients, this was not the case. The
VCP patients carried an abundant load of TDP path-
ology in similar affected areas. The main difference was
the high amount of intranuclear inclusions, compatible
with a TDP proteinopathy type D.
We can assume that the clinical presentation is not
linked to the TDP proteinopathy itself, but rather is the
consequence of the specific cortical areas that are in-
volved. The finding of TDP type A pathology spread
throughout the entire cortex, though to a lesser extent
in the parietal and occipital cortices, can explain the
generalized cortical brain atrophy visualized by struc-
tural imaging [46, 47]. No TDP-43 pathology was found
in the hypoglossal nucleus in our study, supporting the
clinical evidence that motor neuron disease was not
present in this family.
Because TDP-43 inclusions can also be found in car-
riers of VCP and C9orf72 mutations, this suggests that
TDP-43 dysregulation is merely a downstream effect
through a common pathway leading to cell death [48].
The finding of the TDP inclusions is indeed not specific
for underlying gene defects, although the pattern of
TDP inclusions and associated proteinopathies can be
suggestive of a specific gene mutation.
The distribution of the TDP-43 pathology in specific
neocortical structures favors a protein distribution
through neuronal pathways instead of proximity [49].
It is assumed that every specific neurodegenerative
syndrome has its own specific region working as an
“epicenter.” This epicenter is critical in the neuronal
networks, whose normal connectivity profiles resem-
ble the pattern of atrophy in that specific disease, in
our case FTLD. Several network degeneration
mechanisms have been suggested [50]. The presence
Table 4 Demographic data
Patient Sex FH AO (years) Age of death (years) DD (years) Final clinical diagnosis
DR2.3 F F - autosomal dominant 63 72 8.6 PPA (NFV)
DR8.1 F F - autosomal dominant 62 68 5.9 bvFTD
DR25.1 F F - autosomal dominant 69 75 5.4 bvFTD
DR25.5 M F - autosomal dominant 70 73 3,4 bvFTD
DR28.1 M F - autosomal dominant 56 62 6.8 PPA (NFV)
DR205.1 F F 55 61 5.1 PD
DR31.1 M F 65 70 5.6 PPA (NFV)
DR1207.1 F S 62 66 4.4 PPA (NFV)
DR1213.1 M F - autosomal dominant 58 60 2.3 bvFTD
Abbreviations: FH Familial history), F Familial presentation, S Sporadic, AO Age of onset, DD Disease duration in years, PPA Primary progressive aphasia, NFV
Nonfluent variant, bvFTD Behavioral variant frontotemporal dementia








DR2.3 Y (35 py) Y Y N
DR8.1 N N Y Y TIA
DR25.1 ? N Y N Obesity
DR25.5 Y (40 py) N ? ? TIA, stroke
DR28.1 ? N N Y
DR205.1 ? N N N
DR31.1 ? ? ? Y
DR1207.1 N N N Y
DR1213.1 N N N N
Abbreviations: Y Present, N Absent, ? Unknown, py Pack-years, TIA Transient ischemic attack
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of neostriatal lesions could support this hypothesis of
degeneration of neuronal networks because the
striatum has projections to many (frontotemporal)
cortical areas. In addition to cortical abnormalities,
white matter involvement visualized by cerebral im-
aging has been reported in patients carrying a GRN
mutation [21, 51, 52]. Compared with patients with
MAPT mutations, however, GRN mutation carriers
would tend to show less white matter abnormalities
[53]. Because white matter pathology was also seen
on neuroimaging studies in five of our patients, we
investigated the proteinopathy and vessel involvement
in the cortex and white matter. Glial TDP proteino-
pathy is regularly found in patients with GRN
mutations, and this was also the case in all our
patients [53].
Furthermore, we found mild to moderate cerebral
SVD, most pronounced in the frontal lobe, whereas only
normal vascular findings have been described in patients
with FTLD [37, 54]. We assume that the SVD is merely
the consequence of the age of our patients as well as the
comorbidity and presence of cerebrovascular risk factors.
The clinicopathological correlation of the cerebral
vascular pathology is low, but an influence on the dis-
ease mechanism cannot be excluded.
Additionally, a concomitant neuropathological diag-
nosis of AD or PART could be made in all patients.
In every case, however, neuropathological findings
suggestive of AD were mild and could be classified as
not more than A3B1C1. As presented in Table 2, we
assume that there is no correlation between the
neuropathological findings and the clinical symptom-
atology. Five patients could be considered as examples
of PART [40]. One patient presented with a mixed
diagnosis of FTLD-TDP and diffuse Lewy body path-
ology, neocortical type.
We investigated whether the apolipoprotein E (ApoE)
genotype (Table 2) could be related to the AD pathology.
Most patients were homozygous for the ApoE ɛ3 allele
(five of nine). Three patients were carrying the ApoE ɛ2
allele, whereas two patients were heterozygous carriers
of the ApoE ɛ4 risk allele. These latter two patients had
a slightly more severe Montine score for AD pathology,
but without clinical significance.
The high frequency of concomitant pathologies in
GRN mutation carriers, such as the combination of
FTLD with PD or FTLD with AD [55–57], might indi-
cate that loss or partial loss of GRN could advance
pathological features of other neurodegenerative diseases
in an early stage [58]. Petkau and Leavitt reviewed data
on progranulin in neurodegenerative diseases and sug-
gested that GRN variants resulting in decreased progra-
nulin expression might be risk factors for both FTLD
and other dementias and that common GRN variants
can act as modifying factors for age of onset, disease
duration, and risk of disease in ALS, AD, multiple scler-
osis, bipolar disorder, and schizophrenia [59].
The combined occurrence of TDP-43 lesions, AD
pathology, and PD pathology favors the hypothesis that
progranulin is a protective growth factor, with the IVS1
+ 5G > C mutation resulting in a loss of function of pro-
granulin. This results from a cascade of defective bio-
logical processes in an expansion of neurodegenerative
processes leading toward protein deposits and cell
degeneration [60]. However, because AD and PD are
frequent neurodegenerative disorders, a coexistence of
these disorders could be merely a consequence of age-
related risk factors. Different studies have elicited the
co-occurrence of proteinopathies in patients carrying a
GRN mutation [21, 43, 54], whereas other groups could
not confirm this [43].
Clinical presentation
Our clinical data confirm that the age of disease onset is
older than in patients with MAPT or C9orf72 mutations.
Symptomatology started at the age of 62 (range 55–70),
and the disease lasted, on average, 5.3 years (2.30–8.56),
whereas disease in MAPT mutation carriers often starts
earlier. Van Langenhove et al. [25] found a mean onset
age of 56.9 years (range 49–65) in a Belgian FTLD co-
hort with the MAPT mutation, and Whitwell et al. [61]
described an even younger mean onset age of 44 years
(range 24–63) in MAPT mutation carriers. In patients
with a C9orf72 repeat expansion, the described mean
onset age was younger as well. Van Langenhove et al.
[25], and later Van Mossevelde et al. [62], described
mean onset ages of 55.3 years (range 42–69) and
54.3 years (range 29–75), respectively, in Belgian patients
with FTLD with a C9orf72 repeat expansion.
When we compare our findings with those in other
GRN mutation carriers, the findings are similar, although
a broad range of onset ages has been described. In the
whole Belgian GRN founder family, onset ages varying
between 45 and 70 years have been described [8]. Differ-
ent cohorts of GRN mutation carriers have resulted in
different mean onset ages with broad ranges from
55 years (range 37–72) [63] to 64.5 years (range 49–88)
[64]. Even within one family of GRN mutation carriers,
broad ranges have been described for the onset age.
Snowden et al. described a variation in the onset ages in
one family of 23 years [57]. These highly variable onset
ages indicate that there are other modifying factors that
modulate onset age in GRN mutation carriers. GRN mu-
tations are most frequently associated with bvFTD
followed by PPA [21].
In our four patients with a diagnosis of bvFTD, apathy
was one of the initial predominant symptoms. This ob-
servation is in line with previous findings that apathy
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dominates the clinical picture in patients with bvFTD
caused by a GRN mutation [65, 66]. It is in contrast with
bvFTD caused by C9orf72 repeat expansion, in which in-
appropriate behavior and agitation dominate the clinical
presentation [25]. Also, the fact that four of the nine
family members had PPA is highly suggestive for a GRN
mutation [21]. The PPA phenotype in GRN mutation
carriers is most often distinct from that subsumed under
the classical PPA subtypes [67].
Other phenotypes have been associated with GRN mu-
tations and include AD [68], PD [65], corticobasal syn-
drome [69–71], dementia with Lewy bodies [72], and mild
cognitive impairment [73]. Also, several psychiatric syn-
dromes have been associated with GRN mutations [74,
75]. MND is very rarely described in association with
GRN mutations [24, 76]. None of our nine patients had a
concomitant MND. There was one co-occurrence with
PD. Parkinsonism occurs quite frequently in patients with
GRN mutation, but usually later in the disease course,
after development of FTD. In a few cases, parkinsonism
was described as the first or predominant clinical mani-
festation of a GRN mutation. In a cohort of 32 French
GRN mutation carriers, 13 (41%) developed parkinsonism
during their disease course, but it was present at onset in
only 1 patient [77]. Kelley et al. studied patients with
FTLD-UPS and found that parkinsonism was an initial/
early symptom in 3 of 18 patients with a GRN mutation
[64]. Although parkinsonism occurs quite frequently in
patients with FTLD with a GRN mutation, GRN genetic
variability is unlikely to contribute significantly to suscep-
tibility to PD [58].
Six of our patients had subjective or objective signs of
memory loss early or later in the disease course. All of our
patients had mild AD neuropathological features or PART,
but without strong clinicopathological correlation.
Le Ber et al. [77] described that clinical AD features
such as episodic memory disorders are frequent in GRN
mutation carriers (89%). Of the 32 GRN mutation car-
riers evaluated by Le Ber et al., 3 were clinically diag-
nosed with AD because of predominant episodic
memory disorder. In the study of Chen-Plotkin et al., 11
of 97 (11.3%) TDP-positive GRN mutation carriers re-
ceived a clinical diagnosis of AD [24].
Neuropsychological evaluation showed extensive frontal
executive dysfunction in six of seven patients. Neocortical
temporal deficits (economy of speech, comprehension def-
icits, naming deficits) were present in all patients. Apraxia
syndromes were seen in three patients, suggesting parietal
involvement.
Imaging
Cerebral structural imaging demonstrated atrophy in all 9
patients, mostly asymmetric at the frontal and temporal
lobes and often with a parietal cortical involvement.
Similar findings were observed by functional neuroim-
aging, where hypoperfusion and hypometabolism were
asymmetric (left versus right), most explicit in the
frontal and temporal lobes. Again, parietal involve-
ment often was present.
These findings confirm the previously published
data in which parietal involvement [61, 78, 79] and
marked asymmetry of atrophy/hypofunction were
suggested as distinctive features of GRN mutations
[46, 77, 79, 80], as well as a relatively fast evolution
to generalized brain atrophy [47]. Seven patients had
marked asymmetry, and in five of them, the most
pronounced atrophy/hypofunction was present in the
left hemisphere. There seems to be no preferential
side of predominant atrophy/hypofunction in GRN
mutation carriers. Previous studies have demonstrated
predominant left-side involvement [55, 57] as well as
predominant right-side involvement [77, 78, 81, 82].
Conclusions
This study is the first, to our knowledge, in which nine
members of one family carrying a GRN mutation have
undergone exhaustive neuropathological analysis. Our
study made it possible to link this specific GRN muta-
tion to TDP-43 proteinopathy subtype A.
The neocortical pathology in all our patients was very
explicit, with impairment of frontal and temporal corti-
ces to the greatest extent, followed by parietal and, to a
lesser extent, occipital involvement. In all of our cases,
mild hippocampal atrophy was present, but without hip-
pocampal sclerosis. Next to the TDP-43 proteinopathy
subtype A, we found the co-occurrence of other protei-
nopathies, such as PART in five cases, mild AD in four
cases, and Lewy body disease in one case, and we dem-
onstrated the coexistence of small vessel changes, most
explicit in the frontal lobe of every patient. We do not
think that the small vessel pathology is associated with
the GRN mutation, but an age-dependent penetrance
rate has been demonstrated in GRN carriers. Whether
the clinical presentation is the result of the TDP path-
ology exceeding a critical limit of neuronal damage or of
the co-occurrence of age-related AD pathology or PART
or SVD should be further investigated. Because the age
of onset in these patients lies between 55 and 70 years,
an age range within which cerebrovascular risk factors
have their impact, it should be further assessed whether
this cerebrovascular pathology has an influence on the
clinical presentation, onset, and disease course of the
proteinopathy.
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